Division of Clinical Cancer Epidemiology, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Göteborg, Sweden.
Br J Cancer. 2013 May 28;108(10):1964-70. doi: 10.1038/bjc.2013.180. Epub 2013 Apr 30.
The objective of this study is to provide comprehensive overviews of patient-reported urinary symptoms for long-term prostate cancer survivors treated with radiation therapy and for untreated, healthy men.
We performed a population-based cross-sectional study using a study-specific postal questionnaire assessing symptoms among 1007 men consecutively treated at the Sahlgrenska University Hospital, Göteborg, Sweden from 1993-2006 (primary or salvage external beam radiation therapy (EBRT) or EBRT and high-dose rate brachytherapy). We also randomly recruited 350 non-pelvic-irradiated matched control men from the Swedish Total Population Register. Symptom prevalence and prevalence ratios were computed.
Survey participation rate was 89% (874/985) for eligible survivors and 73% (243/332) for eligible controls. Median time from treatment to follow-up was 5 years (range, 1-14 years). Among the 21 investigated symptoms reflecting obstruction, frequency, urgency, pain and incontinence, we found significantly higher prevalence compared with controls for 9 symptoms in the EBRT group, 10 in the EBRT+brachytherapy group and 5 in the salvage EBRT group. The prevalence for a majority of the symptoms was stable over time.
The presented toxicity profiles provide a thorough understanding of patient-reported urinary symptoms that can assist in developing personalised therapy for prostate cancer.
本研究的目的是为接受放射治疗的长期前列腺癌幸存者和未接受治疗的健康男性提供全面的患者报告的尿症状概述。
我们进行了一项基于人群的横断面研究，使用特定于研究的邮寄问卷评估了瑞典哥德堡市萨尔格伦斯卡大学医院连续治疗的 1007 名男性的症状（原发性或挽救性外束放射治疗（EBRT）或 EBRT 和高剂量率近距离放射治疗）。我们还从瑞典总人口登记处随机招募了 350 名非骨盆照射的匹配对照男性。计算了症状的患病率和患病率比。
对符合条件的幸存者进行调查的参与率为 89%（874/985），对符合条件的对照者的参与率为 73%（243/332）。从治疗到随访的中位时间为 5 年（范围，1-14 年）。在反映梗阻、频率、紧迫性、疼痛和尿失禁的 21 种调查症状中，我们发现 EBRT 组有 9 种症状、EBRT+近距离放射治疗组有 10 种症状和挽救性 EBRT 组有 5 种症状的患病率明显高于对照组。大多数症状的患病率随时间稳定。
所呈现的毒性概况提供了对患者报告的尿症状的全面了解，有助于为前列腺癌制定个性化治疗方案。
